Saturday 17 October 2026
Export ALPS’s income statement to Excel — free account
Alps Group Inc.
ALPS Healthcare Biotechnology
Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025. In the quarter to September 2025, EPS fell 609.4% and free cash flow fell 26.5%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow ALPS
Alps Group Inc. (ALPS) P/E ratio
Alps Group Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 160× (March 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 144× | — |
Against its own ten years
Low 0.0×
High 160×
Ten-year median
0.0×
Current reading's percentile
65
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GUTS Fractyl Health, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. | n/m |
| GANX Gain Therapeutics, Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | n/m |
| RNXT RenovoRx, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)